Right heart failure future or investigational therapies
|
Right heart failure Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Right heart failure future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Right heart failure future or investigational therapies |
|
FDA on Right heart failure future or investigational therapies |
|
CDC on Right heart failure future or investigational therapies |
|
Right heart failure future or investigational therapies in the news |
|
Blogs on Right heart failure future or investigational therapies |
|
Risk calculators and risk factors for Right heart failure future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jad Z Al Danaf
Overview
A right ventricular assist device (RVAD) can be a temporary therapy for patients with an acute exacerbation of right heart failure.
Future or Investigational Therapies
- Right ventricular assist device has not yet been tested as a destination therapy in patients with right heart failure. Thus, further studies are needed to determine whether mechanical support devices will benefit individuals with refractory right heart failure and contraindications to heart transplantation [1].
- Emerging medical therapies are being investigated in the field of right heart failure especially metabolic modulators that seem to be the most promising among therapies that improve myocardial energy utilization [2]. Other potential new therapies include myosin activators, Na/K–ATPase inhibitors, adenosine or vasopressin antagonists or micro- RNA modulators[3].
References
- ↑ Skhiri M. et al. Evidence-Based Management of Right Heart Failure: a Systematic Review of an Empiric Fiel. Rev Esp Cardiol. 2010;63(4):451-71
- ↑ Michelakis ED, Wilkins MR, Rabinovitch M. Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation. 2008;118:1486-95.
- ↑ Michelakis ED. Mitochondrial medicine: a new era in medicine opens new windows and brings new challenges. Circulation. 2008;117:2431-4.